SCHEMBL5481306

SCHEMBL5481306

Cc1ccc(S(=O)(=O)N2[C@H](C)CN(c3ccc(OC(F)(F)F)cc3)C[C@@H]2C)cc1CC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.52
PTGDR2 Q9Y5Y4 4/20 0.41
HSD11B1 P28845 1/20 0.41
CHRM2 P08172 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
IDH1 O75874 3/20 0.38
RORC P51449 1/20 0.37
CHRM4 P08173 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
PTGDR Q13258 1/20 0.37
AKR1C3 P42330 1/20 0.37
LIPE Q05469 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5481305 1.00 PPARD (0.52) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL14431186 0.91 PPARD (0.51) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5471264 0.91 PPARD (0.51) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5746202 0.91 PPARD (0.52) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL6348336 0.88 HSD11B1 (0.53) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL5776063 0.88 PPARD (0.50) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL6348338 0.88 HSD11B1 (0.53) PPARDPTGDR2HSD11B1CHRM2CHRM1
SCHEMBL4212887 0.87 PTGDR2 (0.42) PPARDPTGDR2CHRM2CHRM1CHRM5
SCHEMBL13804972 0.87 PTGDR2 (0.42) PPARDPTGDR2CHRM2CHRM1CHRM5
SCHEMBL13805070 0.86 PTGDR2 (0.40) PPARDPTGDR2HSD11B1IDH1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070190079-A1 METHODS FOR THE SELECTIVE MODULATION OF PPAR KALYPSYS, INC. (US) 2007-08-16 US disclosed
US-20070190079-A1 METHODS FOR THE SELECTIVE MODULATION OF PPAR KALYPSYS, INC. (US) 2007-08-16 US disclosed
US-20070190079-A1 METHODS FOR THE SELECTIVE MODULATION OF PPAR KALYPSYS, INC. (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070190079-A1 METHODS FOR THE SELECTIVE MODULATION OF PPAR PPARG, PPARA, PPARD PPARD 3/4885PTGDR2 427/4885HSD11B1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.